Literature DB >> 6822737

Neutralization of influenza virus by normal human sera: mechanisms involving antibody and complement.

D P Beebe, R D Schreiber, N R Cooper.   

Abstract

All normal human sera examined neutralized WS/33 H1N1 influenza virus efficiently by one of two antibody-dependent mechanisms. A minority of the sera contained moderate levels of IgG antibody directed against the viral hemagglutinin that had the ability to directly neutralize the virus. The majority of sera tested contained very low levels of IgG anti-hemagglutinin antibody, which was detectable with a specific ELISA but not by conventional HAI assays. Such IgG antibody was unable to directly neutralize the virus. Studies with agammaglobulinemic serum and with sera depleted of and reconstituted with complement components established essential roles for IgG and the components of the classical complement pathway through C3 for neutralization. The components of the alternative and membrane attack pathways were not needed for neutralization. As anticipated from the requirement for IgG and exclusive mediation of neutralization by the classical pathway, the virus-IgG immune complex activated purified C1. Binding of C3 and C4 to the virus was demonstrated, as was classical pathway-mediated triggering of the alternative pathway, with recruitment of properdin. In addition, the H1N1 influenza virus also directly activated the alternative complement pathway in human serum, leading to C3 and properdin deposition on the viral envelope. Such direct alternative pathway activation also required immunoglobulin. However, the alternative pathway alone was unable to neutralize the virus. Thus, most normal sera examined contain low levels of IgG anti-hemagglutinin antibody, which activate the classical pathway of the complement system and neutralize WS/33 influenza virus by deposition of C3 and C4 on the viral envelope.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6822737

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  26 in total

1.  Complement component C1q enhances the biological activity of influenza virus hemagglutinin-specific antibodies depending on their fine antigen specificity and heavy-chain isotype.

Authors:  Jing Qi Feng; Krystyna Mozdzanowska; Walter Gerhard
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

2.  Natural antibody and complement mediate neutralization of influenza virus in the absence of prior immunity.

Authors:  Jerome P Jayasekera; E Ashley Moseman; Michael C Carroll
Journal:  J Virol       Date:  2007-01-03       Impact factor: 5.103

3.  Analysis of the mechanism of influenza B virus inactivation by guinea pig serum.

Authors:  F Yamamoto Goshima; K Maeno; S Shibata; H Mano; T Suzuki; Y Nishi
Journal:  Arch Virol       Date:  1988       Impact factor: 2.574

Review 4.  Glycan Reactive Natural Antibodies and Viral Immunity.

Authors:  J Stewart New; R Glenn King; John F Kearney
Journal:  Viral Immunol       Date:  2019-12-17       Impact factor: 2.257

5.  A novel vaccine adjuvant for recombinant flu antigens.

Authors:  Stella Chang; John Warner; Lily Liang; Jeff Fairman
Journal:  Biologicals       Date:  2009-03-12       Impact factor: 1.856

6.  Development and application of an enzyme-linked immunosorbent assay for the quantitation of alternative complement pathway activation in human serum.

Authors:  J T Mayes; R D Schreiber; N R Cooper
Journal:  J Clin Invest       Date:  1984-01       Impact factor: 14.808

7.  Cationic lipid/DNA complexes (JVRS-100) combined with influenza vaccine (Fluzone) increases antibody response, cellular immunity, and antigenically drifted protection.

Authors:  Marla Lay; Bernadette Callejo; Stella Chang; David K Hong; David B Lewis; Timothy D Carroll; Shannon Matzinger; Linda Fritts; Christopher J Miller; John F Warner; Lily Liang; Jeffery Fairman
Journal:  Vaccine       Date:  2009-05-09       Impact factor: 3.641

Review 8.  Application of pharmacogenomics to vaccines.

Authors:  Gregory A Poland; Inna G Ovsyannikova; Robert M Jacobson
Journal:  Pharmacogenomics       Date:  2009-05       Impact factor: 2.533

9.  Role of complement and the Fc portion of immunoglobulin G in immunity to Venezuelan equine encephalomyelitis virus infection with glycoprotein-specific monoclonal antibodies.

Authors:  J H Mathews; J T Roehrig; D W Trent
Journal:  J Virol       Date:  1985-09       Impact factor: 5.103

Review 10.  Complement and its role in protection and pathogenesis of flavivirus infections.

Authors:  Panisadee Avirutnan; Erin Mehlhop; Michael S Diamond
Journal:  Vaccine       Date:  2008-12-30       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.